Clean sweep for AbbVie in Humira litigation

15-05-2019

Clean sweep for AbbVie in Humira litigation

casimiropt / Shutterstock.com

Boehringer Ingelheim has become the latest biosimilar maker to resolve litigation over AbbVie’s arthritis treatment Humira (adalimumab).


AbbVie, Humira, Boehringer Ingelheim, adalimumab, licensing agreement, royalties, arthritis, biosimilar, generic competition, antitrust

LSIPR